AU2017294276B2 - Antibody for anti-claudin 18A2 and use thereof - Google Patents

Antibody for anti-claudin 18A2 and use thereof Download PDF

Info

Publication number
AU2017294276B2
AU2017294276B2 AU2017294276A AU2017294276A AU2017294276B2 AU 2017294276 B2 AU2017294276 B2 AU 2017294276B2 AU 2017294276 A AU2017294276 A AU 2017294276A AU 2017294276 A AU2017294276 A AU 2017294276A AU 2017294276 B2 AU2017294276 B2 AU 2017294276B2
Authority
AU
Australia
Prior art keywords
seq
antibody
cell
cells
hu8e5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017294276A
Other languages
English (en)
Other versions
AU2017294276A1 (en
Inventor
Hua Jiang
Zonghai Li
Zhimin Shi
Huamao Wang
Peng Wang
Linlin YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crage Medical Co Ltd
Original Assignee
Crage Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Crage Medical Co Ltd filed Critical Crage Medical Co Ltd
Publication of AU2017294276A1 publication Critical patent/AU2017294276A1/en
Assigned to CAFA THERAPEUTICS LIMITED reassignment CAFA THERAPEUTICS LIMITED Request for Assignment Assignors: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTE
Assigned to CRAGE MEDICAL CO., LIMITED reassignment CRAGE MEDICAL CO., LIMITED Request for Assignment Assignors: CAFA THERAPEUTICS LIMITED
Application granted granted Critical
Publication of AU2017294276B2 publication Critical patent/AU2017294276B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2017294276A 2016-07-08 2017-07-10 Antibody for anti-claudin 18A2 and use thereof Active AU2017294276B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610536449 2016-07-08
CN201610536449.9 2016-07-08
AUPCT/CN2017/082024 2017-04-26
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法
PCT/CN2017/092381 WO2018006882A1 (zh) 2016-07-08 2017-07-10 抗密蛋白18a2的抗体及其应用

Publications (2)

Publication Number Publication Date
AU2017294276A1 AU2017294276A1 (en) 2019-02-28
AU2017294276B2 true AU2017294276B2 (en) 2024-08-01

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017294276A Active AU2017294276B2 (en) 2016-07-08 2017-07-10 Antibody for anti-claudin 18A2 and use thereof

Country Status (13)

Country Link
US (2) US11111295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3483182B1 (cg-RX-API-DMAC7.html)
JP (1) JP7587921B2 (cg-RX-API-DMAC7.html)
KR (1) KR102723896B1 (cg-RX-API-DMAC7.html)
CN (1) CN109790222B (cg-RX-API-DMAC7.html)
AU (1) AU2017294276B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000327A8 (cg-RX-API-DMAC7.html)
CA (1) CA3030257A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000061A1 (cg-RX-API-DMAC7.html)
ES (1) ES2979068T3 (cg-RX-API-DMAC7.html)
IL (1) IL264144B2 (cg-RX-API-DMAC7.html)
SG (1) SG11201900171QA (cg-RX-API-DMAC7.html)
WO (1) WO2018006882A1 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264144B2 (en) * 2016-07-08 2023-11-01 Carsgen Therapeutics Co Ltd Antibody 18A2 against CLAUDIN and its use
WO2019149279A1 (zh) 2018-02-02 2019-08-08 科济生物医药（上海）有限公司 细胞免疫治疗的组合
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
WO2019170147A1 (zh) 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
BR112020014591A2 (pt) * 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
US20220127570A1 (en) 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
AU2019271819A1 (en) 2018-05-15 2021-01-14 Crage Medical Co., Limited Genetically engineered cell and application thereof
JP7117795B2 (ja) 2018-05-18 2022-08-15 ラノバ メディシンズ リミテッド 抗クローディン１８．２抗体およびその使用
AU2019310855A1 (en) 2018-07-24 2021-03-11 Crage Medical Co., Limited Method for treating tumor using immune effector cell
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
EP3878863A4 (en) * 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
JP7458399B2 (ja) * 2018-12-07 2024-03-29 ゼットリップ ホールディング リミテッド 抗クローディン抗体及びそれらの使用
EP3892333A4 (en) 2018-12-07 2022-11-30 CRAGE medical Co., Limited Tumor combined immunotherapy
US12297265B2 (en) 2018-12-28 2025-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
MX2021007939A (es) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
EP3909590A4 (en) * 2019-01-07 2022-11-16 CRAGE medical Co., Limited ASSOCIATION FOR CELLULAR IMMUNOTHERAPY
CN113817061B (zh) * 2019-01-15 2022-11-04 浙江道尔生物科技有限公司 一种抗cld18a2单域抗体及其抗肿瘤用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN113645996B (zh) * 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法
EP3919517A4 (en) * 2019-02-01 2023-03-15 CRAGE medical Co., Limited TCR FUSION PROTEIN AND CELL WITH TCR FUSION PROTEIN EXPRESSION
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
EP3947471A4 (en) * 2019-03-27 2023-03-15 The Trustees of The University of Pennsylvania TN-MUC1 CHIMERIC ANTIGEN RECEPTOR (CAR) T-LYMPHOCYTE THERAPY
CN113784980B (zh) * 2019-03-29 2024-04-30 凡恩世制药(北京)有限公司 人源化抗Claudin18.2嵌合抗原受体及其用途
JP7592022B2 (ja) * 2019-04-01 2024-11-29 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗クローディン１８．２抗体及びその用途
US20220372112A1 (en) * 2019-04-19 2022-11-24 Keymed Biosciences Co., Ltd. Tumor therapeutic agent and use thereof
KR20220024010A (ko) 2019-05-16 2022-03-03 치루 파머수티컬 컴퍼니 리미티드 클라우딘 18a2에 대한 항체 및 그의 용도
EP3978532A4 (en) * 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
US12312402B2 (en) 2019-05-30 2025-05-27 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets Claudin 18.2
IL313807A (en) * 2019-07-17 2024-08-01 Univ California Claudin 18 antibodies and methods for cancer treatment
AU2020329466B2 (en) * 2019-08-12 2024-08-01 Abl Bio Inc. Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
WO2021088927A1 (en) * 2019-11-05 2021-05-14 Lanova Medicines Limited Company Antibody-drug conjugates targeting claudin 18.2
WO2021104511A1 (zh) * 2019-11-29 2021-06-03 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
CA3159465A1 (en) 2019-12-06 2021-06-10 Lukas BAMMERT Humanized cldn18.2 antibodies
AU2020410998A1 (en) 2019-12-23 2022-06-16 Sotio Biotech A.S. Tumor-specific Claudin 18.2 antibodies
EP4086287A4 (en) * 2020-01-03 2024-03-06 CRAGE medical Co., Limited ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF
EP4105238A4 (en) * 2020-02-10 2024-03-27 Shanghai Escugen Biotechnology Co., Ltd. CLAUDIN 18.2 ANTIBODIES AND THEIR USE
CN116096751A (zh) * 2020-02-25 2023-05-09 璟尚生物制药公司 三特异性t细胞接合器
EP4151235A4 (en) * 2020-05-15 2025-08-06 Sichuan Kelun Biotech Biopharmaceutical Co Ltd ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS USE
TWI809426B (zh) * 2020-06-19 2023-07-21 大陸商信達生物製藥（蘇州）有限公司 抗Ｃｌａｕｄｉｎ１８.２抗體以及其用途
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
WO2022011531A1 (zh) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
US20230310600A1 (en) 2020-08-07 2023-10-05 Crage Medical Co., Limited Engineered cells and method for engineering cells
EP4222174A4 (en) * 2020-09-30 2025-02-12 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc The CD45–GATE vehicle activates a protease
MX2023007644A (es) 2020-12-23 2023-07-07 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2.
IL303853A (en) 2021-01-29 2023-08-01 Allogene Therapeutics Inc KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
US20240181055A1 (en) * 2021-04-08 2024-06-06 Crage Medical Co., Limited Cellular immunotherapy use
WO2022218375A1 (zh) * 2021-04-15 2022-10-20 克莱格医学有限公司 嵌合t细胞受体及其应用
WO2023274303A1 (zh) 2021-06-29 2023-01-05 科济生物医药（上海）有限公司 调控细胞生理活动的嵌合多肽
CN113788894B (zh) * 2021-09-03 2022-08-05 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
JP2024540062A (ja) * 2021-11-05 2024-10-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｃｌｄｎ１８．２抗体及びその用途
WO2023213280A1 (zh) * 2022-05-06 2023-11-09 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
CN119654342B (zh) * 2022-07-28 2025-07-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
CN119654406A (zh) 2022-07-29 2025-03-18 艾洛基治疗公司 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞
AU2024210908A1 (en) 2023-01-18 2025-08-21 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN112979828B (zh) * 2014-07-17 2025-04-29 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
KR20180088445A (ko) 2015-12-04 2018-08-03 애브비 스템센트알엑스 엘엘씨 신규한 항-클라우딘 항체 및 사용 방법
CN108884459B (zh) * 2016-04-26 2024-04-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
IL264144B2 (en) * 2016-07-08 2023-11-01 Carsgen Therapeutics Co Ltd Antibody 18A2 against CLAUDIN and its use
WO2019170147A1 (zh) * 2018-03-09 2019-09-12 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
EP3909590A4 (en) * 2019-01-07 2022-11-16 CRAGE medical Co., Limited ASSOCIATION FOR CELLULAR IMMUNOTHERAPY
US20230272341A1 (en) * 2020-08-10 2023-08-31 Crage Medical Co., Limited Multifunctional immune effector cell and use thereof

Also Published As

Publication number Publication date
US20190233511A1 (en) 2019-08-01
RU2019101430A3 (cg-RX-API-DMAC7.html) 2021-05-17
NZ750420A (en) 2025-06-27
AU2017294276A1 (en) 2019-02-28
US11111295B2 (en) 2021-09-07
IL264144B2 (en) 2023-11-01
CA3030257A1 (en) 2018-01-11
SG11201900171QA (en) 2019-02-27
CN109790222B (zh) 2022-03-15
EP3483182A4 (en) 2020-07-29
IL264144B1 (en) 2023-07-01
CL2019000061A1 (es) 2019-05-03
JP2019531084A (ja) 2019-10-31
JP7587921B2 (ja) 2024-11-21
KR20190038564A (ko) 2019-04-08
IL264144A (en) 2019-02-28
BR112019000327A8 (pt) 2022-10-18
EP3483182A1 (en) 2019-05-15
ES2979068T3 (es) 2024-09-24
EP3483182B1 (en) 2024-05-08
RU2019101430A (ru) 2020-08-10
WO2018006882A1 (zh) 2018-01-11
KR102723896B1 (ko) 2024-11-01
US20220185880A1 (en) 2022-06-16
CN109790222A (zh) 2019-05-21
BR112019000327A2 (pt) 2019-08-13

Similar Documents

Publication Publication Date Title
AU2017294276B2 (en) Antibody for anti-claudin 18A2 and use thereof
AU2019253562B2 (en) Methods and compositions comprising a viral vector for expression of a transgene and an effector
US11484552B2 (en) Use of trans-signaling approach in chimeric antigen receptors
CN118165113B (zh) 一种改善免疫应答细胞功能的方法
JP7141725B2 (ja) 変異ｃｄ２８共刺激ドメインを有するキメラ抗原受容体
WO2018133877A1 (zh) 靶向bcma的抗体及其应用
AU2018221110B2 (en) Antibody Targeting IL-13RA2 and Use Thereof
EP3962955A1 (en) Antigen specific cd19-targeted car-t cells
AU2019312411A1 (en) Nef-containing T cells and methods of producing thereof
WO2018149358A1 (zh) 靶向il-13ra2的抗体及其应用
RU2793445C2 (ru) Антитело против клаудина 18а2 и его применение
HK40002280B (zh) 抗密蛋白18a2的抗体及其应用
HK40002280A (zh) 抗密蛋白18a2 的抗体及其应用
HK40017077A (en) Il-13ra2-targeted antibody and application thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CAFA THERAPEUTICS LIMITED

Free format text: FORMER APPLICANT(S): SHANGHAI CANCER INSTITUTE; CARSGEN THERAPEUTICS CO., LTD.

PC1 Assignment before grant (sect. 113)

Owner name: CRAGE MEDICAL CO., LIMITED

Free format text: FORMER APPLICANT(S): CAFA THERAPEUTICS LIMITED

FGA Letters patent sealed or granted (standard patent)